Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited reports news on its clinical-stage immunology pipeline for autoimmune and inflammatory diseases. The company develops dual-pathway antibody candidates, led by tibulizumab (ZB-106), which targets IL-17A and BAFF and is being evaluated in Phase 2 studies for hidradenitis suppurativa and systemic sclerosis. Its additional clinical-stage candidates include crebankitug (ZB-168), targeting IL-7R, and torudokimab (ZB-880), targeting IL-33.
Recurring updates cover clinical study designs and presentations, financial results, corporate presentations, leadership and board changes, equity incentive grants, and capital-raising activity involving Class A ordinary shares and pre-funded warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zura Bio Limited (Nasdaq: ZURA) has licensed tibulizumab, an anti-IL-17 and anti-BAFF dual antagonist, from Eli Lilly. The compound will be designated as ZB-106 and has already undergone two Phase 1b studies demonstrating an acceptable safety profile. Zura plans to initiate a Phase 2 study for ZB-106 in Systemic Sclerosis in 2024. Additionally, the company has announced a private placement financing to raise approximately $80 million, selling around 18.8 million Class A ordinary shares and pre-funded warrants. The financing is expected to enhance Zura’s cash reserves to approximately $120 million, sufficient to fund operations through 2026. The offering is led by multiple investment firms, and shares are priced at $4.25.
Zura Bio Limited (Nasdaq: ZURA) has appointed Michael D. Howell, Ph.D., as the new Chief Scientific Officer and Head of Translational Science. With over two decades of experience, Dr. Howell will spearhead the scientific strategy and translational research efforts at Zura Bio. Prior to this role, he was a scientific advisor during the company's formation in 2022. His extensive background includes leadership positions at DermTech, Incyte Corporation, and AstraZeneca. Zura Bio focuses on developing therapies for immune and inflammatory disorders and is advancing its pipeline, including Phase 2 programs like ZB-168 and torudokimab. CEO Someit Sidhu expressed confidence in Dr. Howell's expertise to drive the company’s science and clinical development forward.
Zura Bio Limited has successfully completed its business combination with JATT Acquisition Corp, announced on March 21, 2023. Prior to the merger, JATT's public shareholders redeemed 98.7% of their Class A ordinary shares, totaling 13,617,502 shares. Post-combination, Zura is advancing its immunology assets into Phase 2 development, focusing on ZB-168, an anti-IL7R α inhibitor targeting various inflammatory disorders, and torudokimab, a monoclonal antibody neutralizing IL33. Zura's growth is backed by promising Phase 1b results in Type 1 Diabetes, showcasing a favorable safety profile.
Zura Bio Limited, a clinical-stage biotechnology company focused on immunology, has completed its business combination with JATT Acquisition Corp. The merger, approved by JATT's shareholders on March 16, 2023, results in approximately $65 million in gross cash proceeds to support R&D initiatives and potential acquisitions. The combined entity will trade under the ticker symbol ZURA on Nasdaq starting March 21, 2023. The funds will be used for the clinical development of Zura's pipeline candidates, ZB-168 and torudokimab, with leadership from former Arena Pharmaceuticals executives. This milestone aims to enhance the company's immunology portfolio.